ArticleBMC anesthesiology2026
Compatibility and stability of ciprofol with different concentrations of remifentanil or esketamine.
Article in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCombination anesthesia with ciprofol, remifentanil, and esketamine enhances clinical efficacy but poses stability risks due to the emulsion formulation. Given the lack of compatibility data, this study investigated the physicochemical stability of ciprofol mixed with varying concentrations of remifentanil or esketamine.
methodsCiprofol emulsions were mixed with varying concentrations of esketamine or remifentanil at a volume ratio of 1:1. The admixtures were prepared at room temperature (25 ± 1 °C) under ambient light, and samples were collected at predefined time points (0, 2, 4, 6, and 8 h) for stability analysis. To assess the stability of the mixtures, drug concentrations (measured by high-performance liquid chromatography), macroscopic and microscopic appearance, pH, mean particle diameter (MPD), polydispersity index (PDI), zeta potential, and osmolality were evaluated.
resultsOver the 8-h period, no visual changes were observed in any mixture, and drug concentrations remained between 96% and 104% of the initial value. The MPD remained stable at 205 ± 7 nm, with a uniform particle size distribution (PDI = 0.1 ± 0.03). Notably, in contrast to the esketamine group, the remifentanil group exhibited significant changes in pH and osmolality (P < 0.05), along with a significantly lower absolute zeta potential. Microscopic analysis further revealed mild droplet aggregation in the remifentanil group.
conclusionsCiprofol exhibits chemical stability and acceptable physical compatibility with esketamine or remifentanil at the tested concentrations for up to 8 h. However, given the mild physical instability (e.g., droplet aggregation) observed in ciprofol-remifentanil mixtures, prolonged storage is not recommended, because it may affect their stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.